Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MIF | P14174 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289598 | 0.87 | SIRT1 (0.69) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL23752360 | 0.84 | SIRT1 (0.83) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL23752358 | 0.84 | SIRT1 (0.83) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL28423171 | 0.80 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL6571363 | 0.80 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL6571360 | 0.80 | MAPT (0.74) | KMT2AMAPTMEN1KDM4EMIF | |
| SCHEMBL7949337 | 0.80 | KMT2A (0.78) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL7949340 | 0.80 | KMT2A (0.78) | SIRT1KMT2AMAPTMEN1KDM4E | |
| SCHEMBL28029715 | 0.78 | KDM1A (0.71) | KMT2AMAPTMEN1KDM4ENPC1 | |
| SCHEMBL19283294 | 0.77 | KMT2A (0.67) | KMT2AMAPTMEN1KDM4EMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263636-B2 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | IMTM GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| EP-2105441-A1 | Alanyl aminopeptidase and dipeptidylpeptidase IV dual inhibitors for the treatment of immunological, inflammatory, neuronal and other illnesses | IMTM GmbH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-04-05 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005034940-A2 | DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | SIRT1 3565/4885KMT2A 4135/4885MAPT 1306/4885 |
| US-20070078130-A1 | Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases | DNPEP, PREP, ANPEP | SIRT1 3974/4885KMT2A 3636/4885MAPT 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.